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Influenza virus genomic RNA segments are packaged into ribonucleoprotein (RNP) structures by the PB1, PB2, and PA subunits of an
RNA polymerase and a single-strand RNA-binding nucleoprotein (NP). Assembly and function of these ribonucleoproteins depend on a
complex set of protein–protein and protein–RNA interactions. Here, we identify new functional domains of PB2. We show that PB2
contains two regions that bind NP and also identify a novel PB1 binding site. The regions of PB2 responsible for binding NP and PB1 show
considerable overlap, and binding of NP to the PB2 fragments could be outcompeted by PB1. The binding domains of PB2 acted as trans-
dominant inhibitors of viral gene expression, and consistent with the in vitro binding data, their inhibitory activity depended on the
concentration of wild-type PB2, NP, and PB1. This provides evidence for functionally significant and potentially regulatory interactions
between PB2 and NP.
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Influenza A virus possesses a single-strand RNA genome
comprised of eight individual segments. These vRNA seg-
ments are negative polarity and are neither capped nor
polyadenylated. They are always found in the form of
ribonucleoprotein (RNP) particles with four core viral
polypeptides. These are the PB1, PB2, and PA subunits of
an RNA-dependent RNA polymerase, and a single-strand
RNA binding nucleoprotein (NP). These four polypeptides
are necessary and sufficient to catalyse transcription of the
vRNA segments into capped and polyadenylated mRNA
and to replicate them via an uncapped and non-polyadeny-
lated cRNA replicative intermediate (Huang et al., 1990).
The process of mRNA transcription is understood in some
detail. A capped RNA fragment is generated from a host cell
mRNA through an RNA endonuclease activity present in0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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synthesis. Polyadenylation is achieved by repetitive tran-
scription of a poly(U) stretch just adjacent to the 5V-end of
the vRNA segments, most likely because of a self-imposed
steric block arising from the polymerase remaining bound to
the 5V-end of the genomic template (Fodor et al., 1994; Poon
et al., 1998; Pritlove et al., 1999; Tiley et al., 1994).
Genome replication is less well understood, but requires
viral protein synthesis and unprimed transcription initiation
(recently reviewed by Elton et al., 2002).
In many cases, individual functions have been ascribed to
specific RNP polypeptides. PB1 is the nucleotide polymer-
ase and probably the RNA endonuclease (Li et al., 2001;
Ulmanen et al., 1981), although PB2 recognizes the cap
structures on host cell mRNAs (Blaas et al., 1982; Ulmanen
et al., 1981). Mutations in the PA subunit of the polymerase
affect both genome replication and mRNA transcription
(Fodor et al., 2002; Mahy, 1983), and although the protein
does not have a specifically identified role during transcrip-
tion, there is evidence that it stimulates binding of PB1 to 5V-
promoter sequences (Lee et al., 2002). PA is also associated
with a protease activity of uncertain function (Hara et al.,
2001; Sanz-Ezquerro et al., 1995). NP primarily has a
structural role in maintaining the organization of the RNP,
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genome replication (reviewed by Portela and Digard, 2002).
However, all four polypeptides are required for the tran-
scriptional life-cycle of the virus (Huang et al., 1990), and
their function is rendered mutually interdependent through a
network of protein–protein interactions. The polymerase
functions as a trimer containing one copy of each of the
three P proteins (Detjen et al., 1987; Honda et al., 1990),
with PB1 acting as the backbone of the complex (Digard et
al., 1989). NP forms homo-oligomers (Elton et al., 1999a;
Ruigrok and Baudin, 1995) and also interacts with two of
the three polymerase (P) proteins (Biswas et al., 1998;
Medcalf et al., 1999). These protein–protein interactions
are likely to be functionally significant. Genetic analysis
indicates that the PB1–PA interaction is essential for virus
replication (Perez and Donis, 2001). Moreover, there is
evidence for allosteric interactions between the P proteins,
as binding of PB1 and PB2 to viral RNA and cellular
mRNAs, respectively, modulates the activities of the other
protein (Cianci et al., 1995; Lee et al., 2003; Li et al., 1998;
Penn and Mahy, 1984; Rao et al., 2003).
In the absence of atomic-resolution structures for any of
the protein components of the RNP, several studies have
employed genetic and biochemical means to identify the
regions of the polypeptides that are responsible for recog-
nizing their partners. In the polymerase complex, sequences
have been identified at the N- and C-termini of PB1 that
bind to the C- and N-termini of PA and PB2, respectively
(Gonzalez et al., 1996; Perez and Donis, 1995; Toyoda et
al., 1996). Within NP, two regions have been implicated in
multimerization (Elton et al., 1999a), although multiple
sequences have been identified as capable of binding to
PB2 (Biswas et al., 1998). In this study, we set out to
identify the PB2 sequences responsible for interacting with
NP. We show that two separate regions of PB2 function as
NP-binding sites. Furthermore, one of these sequences
closely overlaps a previously identified PB1-binding site
while the other contains a hitherto unrecognized PB1-
interacting domain. Consistent with the sequence overlap
of the binding sites, both PB2 domains could bind either NP
or PB1, but not both simultaneously. The PB2 fragments
acted as trans-dominant inhibitors of influenza virus gene
expression in cells, and their inhibitory activity was out-
competed by an excess of wild-type PB2. The inhibitory
activity of the N-terminal fragment also depended on the
concentration of NP and PB1. This provides evidence for
functionally important protein–protein interactions among
PB2, NP, and PB1.Fig. 1. NP-binding activity of PB2 deletion mutants. Radiolabeled cell
lysates from Xenopus oocytes microinjected with mRNAs encoding WT, or
deleted PB2 polypeptides were analyzed by SDS-PAGE and autoradiog-
raphy after precipitation with GST ( ), GST–NP (N), or anti-PB2 sera
(+, except panel (a), lanes 7 and 10, where GST-1N683 was used). Black
arrows indicate PB2 polypeptides, white arrows a Xenopus glutathione–
sepharose binding protein. (a) WT and C-terminally deleted PB2 molecules.
(b) N-terminal and internal PB2 fragments.Results
Identification of the NP-binding regions of PB2
We and others have identified a protein–protein interac-
tion between the influenza virus NP and PB2 polypeptides(Biswas et al., 1998; Elton et al., 1999b; Medcalf et al.,
1999). The functional significance of this interaction is not
yet known, although it has been suggested to be important
in the switch between mRNA and cRNA synthesis (Biswas
et al., 1998; Mena et al., 1999), or as a structural element
during the formation or transcription of RNP structures
(Medcalf et al., 1999). To further delineate the interaction,
we determined the regions of PB2 that bind to NP, by
examining the ability of PB2 fragments to bind to full-
length NP. To provide a source of radiolabeled PB2,
Xenopus oocytes were microinjected with synthetic mRNAs
derived from cDNA copies of influenza A segment 1 and
incubated in the presence of 35S-methionine. Cell extracts
were subsequently prepared and tested for their ability to
bind to glutathione transferase (GST) or a GST–NP fusion
protein immobilized on glutathione sepharose. As a positive
control for expression of the desired PB2 fragment, aliquots
of the extract were also immunoprecipitated with antisera
directed against PB2, or in certain cases, precipitated using a
GST–PB1 fusion protein (see later). As we have previously
shown (Medcalf et al., 1999), full-length PB2 was precip-
itated by GST–NP but not by GST (Fig. 1a, lanes 2 and 3).
In addition, GST–NP precipitated as much PB2 as anti-PB2
sera but as few cellular polypeptides (compare lanes 1 and 3
and see Fig. 4a for an example of a total cell extract),
indicating that the GST–NP/PB2 interaction is efficient and
Fig. 3. Ability of PB2 fusion proteins to bind NP. GST or MBP fusion
proteins (approximately 0.3 Ag per reaction) were tested for their ability to
bind radiolabeled in vitro translated NP. Aliquots of NP were analyzed by
SDS-PAGE and (a) autoradiography, (b) staining of the same gel with
Coomassie brilliant blue before (T) and after precipitation with the
indicated fusion proteins. Arrows indicate NP and the positions of
molecular mass markers (kDa) as labeled.
Fig. 2. Summary of the ability of PB2 deletion mutants to bind PB1 and NP.
The coding sequences of the indicated mutants are depicted by boxes
relative to the WT protein. Binding activity is summarized as essentially
WT (+), clearly above background but less than WT (+) and no significant
binding activity ( ).
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truncated PB2 mutants to bind NP. Removal of the C-
terminal 76 residues had little apparent effect on the ability
of PB2 to bind NP (Fig. 1a, C683, lanes 4–6). Increasing
removal of C-terminal sequences, ranging from 169 to 490
amino acids, also caused little decrease in binding activity
(C590, 400, 320; data not shown but summarized in Fig. 2,
C269, Fig. 1a, lanes 7–9). However, further truncation of
the polypeptide to leave only the N-terminal 131 residues
reduced binding to background levels (Fig. 1a, C131, lanes
10–12). In the converse experiment, we tested the effects of
progressive N-terminal truncation of PB2. Removal of the
first 282 residues to generate PB2 N283 had little effect on
NP binding (Fig. 1b, lanes 1–3). Similarly, polypeptides
with N-termini beginning at PB2 codons 400 or 488 also
bound well to GST–NP (N400, Fig. 1b, lanes 4–6; N488,
summarized in Fig. 2). Further truncation to leave just the
C-terminal 170 residues of PB2 reduced but did not abolish
binding (N580, Fig. 1b, lanes 7–9). When the effects of
simultaneous N- and C-terminal truncations of PB2 were
tested, a fragment of PB2 comprising residues 283–683 still
bound efficiently to NP (Fig. 2). However, removal of
further C-terminal sequences to generate the polypeptide
283–590 abolished binding activity (Fig. 1b, lanes 10–12).
Similarly, an N-terminal internal fragment of PB2 contain-
ing amino acids 29–258 showed no NP-binding activity
(Fig. 2). Overall, these data suggest that PB2 contains
independent N- and C-terminal regions capable of binding
NP, located between residues 1–269 and 580–683, respec-tively (Fig. 2). In confirmation of this, identical results were
obtained when the mutant PB2 polypeptides were expressed
in rabbit reticulocyte lysate (data not shown), indicating that
the pattern of binding specificities obtained was not peculiar
to Xenopus oocyte expressed material.
To facilitate further analysis of the PB2 NP-binding
regions, we next expressed and affinity purified the appro-
priate sequences from Escherichia coli as gene fusions with
either GST or maltose-binding protein (MBP). C-terminal
PB2 sequences were successfully obtained with the last 180
amino acids of PB2 fused to MBP or GST (MBP-PB2-C,
Fig. 3b, lane 9; GST-PB2-C; data not shown), or as the last
271 residues of PB2 fused to GST (GST-PB2-CL; data not
shown). Expression of the N-terminus of PB2 was achieved
by fusing the first 258 residues of the polypeptide to GST
(GST-PB2-N), although the protein co-purified with sub-
stantial quantities of a presumed proteolytic product
corresponding closely in size to native GST (Fig. 3b,
compare lanes 3 and 8). Next, we tested the abilities of
these polypeptides to bind to NP translated in vitro in rabbit
reticulocyte lysate. Aliquots of the radiolabeled NP were
mixed with the PB2 fusion proteins, or as controls, with
nonfused MBP or GST, GST–NP, GST fused to C-terminal
sequences of PB1 (GST-1N683 and -1N712), or GST fused
to an irrelevant papillomavirus protein (GST-16E6). After
E. Poole et al. / Virology 321 (2004) 120–133 123incubation, the fusion proteins were precipitated by the
addition of glutathione sepharose or amylose resin as
appropriate, washed, and bound protein examined by
SDS-PAGE. Coomassie-blue staining of total protein
showed that the fusion proteins were precipitated in approx-
imately equal quantities (Fig. 3b). Autoradiography con-
firmed that as previously shown (Elton et al., 1999a),
radiolabeled NP bound efficiently to GST–NP (Fig. 3a,
lane 2), but not to GST or MBP alone (lanes 3 and 4). Only
trace quantities of NP bound to GST fused to human
papillomavirus type 16 E6 protein or to GST fused to C-
terminal sequences from influenza virus PB1 protein (lanes
5–7). However, substantial quantities of NP were bound by
the N- and C-termini of PB2 fused to GST and MBP,
respectively (lanes 8 and 9). This confirms the results of
experiments analyzing the binding of radiolabeled PB2
fragments to GST–NP (Fig. 1), and shows that both N-
and C-terminal regions of PB2 specifically bind NP.
Relationship of NP- and PB1-binding regions of PB2
PB2 also interacts with the PB1 subunit of the RNA
polymerase (Digard et al., 1989), and similarly to one of the
NP-binding regions identified above, a PB1-binding region
has been identified in the N-terminal 249 amino acids of
PB2 (Ohtsu et al., 2002; Toyoda et al., 1996). We therefore
wished to determine what relationship the NP-binding
domains of PB2 had to the sequences important for binding
PB1. Accordingly, we examined the ability of the PB2
fusion proteins to bind PB1. Radiolabeled PB1 from
extracts of microinjected Xenopus oocytes (Fig. 4a, lane
1) was incubated with the various fusion proteins and
examined for binding as above. As a positive control, an
aliquot of the cell extract was immunoprecipitated with anti-
PB1 sera (Fig. 4a, lane 2). No detectable PB1 was bound by
GST or MBP alone (lanes 3 and 7, respectively) or by
irrelevant fusion proteins such as GST16E6 or MBP fused
to the coxsackie/adenovirus receptor (data not shown). In
contrast, PB1 was efficiently bound by the fusion protein
containing sequences from the N-terminus of PB2 (lane 5),
confirming the results of Toyoda et al. (1996). However,
PB1 also bound to the fusion proteins containing C-terminal
residues of PB2, either linked to GST (lane 4) or MBP (lane
6). Identical results were obtained using PB1 synthesized in
E. coli or BHK cells as a target (data not shown), suggesting
the existence of additional PB1-binding sites in PB2 to that
already identified (Ohtsu et al., 2002; Toyoda et al., 1996).
To further examine the possibility of additional PB1-
binding sites in PB2, we employed a co-immunoprecipita-
tion assay using material from cells co-expressing both
proteins. Xenopus oocytes were microinjected with synthet-
ic mRNAs derived from plasmids pKT1 and 2, and incu-
bated in the presence of 35S-methionine. Cell extracts were
then analyzed by SDS-PAGE and autoradiography after
immunoprecipitation with antisera specific for PB1 or
PB2. When extracts from oocytes co-expressing wild-typePB1 and PB2 were analyzed, both polypeptides were
immunoprecipitated by either antiserum (Fig. 4b, lanes 3
and 4), indicating that the two proteins were associated. The
coprecipitation was specific, as no precipitation of PB1 or
PB2 by the heterologous antiserum was observed when the
polypeptides were expressed in isolation (Fig. 4b, lanes 1, 2,
5, and 6), and neither were significant quantities of Xenopus
polypeptides precipitated with either P protein. This repro-
duces our earlier finding that PB1 and PB2 interact in the
absence of PA (Digard et al., 1989). Next, we tested the
effect of removing the previously identified N-terminal
PB1-binding domain from PB2. A mutant PB2 molecule
lacking the first 282 amino acids still efficiently and
specifically co-immunoprecipitated with PB1 (Fig. 4c, lanes
1–4). Thus, the minimal PB1-binding domain identified
previously (Toyoda et al., 1996) is not the only PB2
sequence capable of interacting with PB1. In confirmation
of the results obtained with the GST-PB2 fusion proteins,
further N-terminal truncation of PB2 indicated that the
amino-terminal two-thirds of the protein was dispensable
for PB1 binding. Mutants lacking sequences upstream of
amino acid 487 still specifically coprecipitated with PB1
(N400, data not shown but summarized in Fig. 2, N488; Fig.
4c, lanes 5–8). Further truncation of PB2 resulted in a
polypeptide that still bound PB1, but in a less stable fashion
as both polypeptides were immunoprecipitated when anti-
PB2 sera were used (Fig. 4c, N580, lane 12), but not when
anti-PB1 sera were used (lane 11, possibly due to disruption
of a weak interaction by the latter serum). However,
removal of C-terminal sequences from an already N-termi-
nally deleted mutant resulted in polypeptides that no longer
bound PB1, as evidenced by the lack of cross-precipitation
of the two P proteins (Fig. 4c, 283–683, lanes 15 and 16,
283–590, 29–258 summarized in Fig. 2). Thus, PB2
contains an additional PB1-binding site located toward its
C-terminus. Progressive C-terminal deletion mutagenesis of
PB2 confirmed the presence of a PB1-binding site at the N-
terminus of the polypeptide, as proteins truncated at amino
acids 683, 590, 400, 320, 269, or 131 all still coprecipitated
with PB1 (N269, N131, Fig. 1a, lanes 7–12; N683, N590,
N400; N320, summarized in Fig. 2). Overall therefore, PB2
contains two independent binding sites for PB1, located
similarly to the NP-binding sites at the N- and C-termini of
the polypeptide (Fig. 2).
Competitive protein–protein interactions among PB2, NP,
and PB1
The experiments described above identified two separate
binding sites in PB2 for each of NP and PB1 that mapped to
similar regions of PB2. Although differences in the binding
activities of certain PB2 polypeptides were noticed (e.g.,
283–590; Fig. 2), the N-terminal 269 and C-terminal 180
amino acids of PB2 encompass both NP and PB1 binding
activity (Figs. 1–4). Thus, it was of interest to determine
whether these regions of PB2 could bind both polypeptides
Fig. 4. PB1-binding regions of PB2. (a) Radiolabeled oocyte lysates containing PB1 were analyzed by SDS-PAGE and autoradiography before (Total) or after
precipitation with F1 anti-PB1 serum (a-PB1) or the indicated fusion proteins. (b, c) Co-immunoprecipitation analysis of PB2–PB1 interactions. SDS-PAGE
and autoradiographic analysis of polypeptides immunoprecipitated from lysates of oocytes microinjected with the indicated combinations of mRNAs encoding
wild-type PB1 and wild-type (b) or truncated (c) PB2. Samples were immunoprecipitated with anti-PB1 (a1) or anti-PB2 (a2) sera. Black arrows indicate PB1,
white arrows PB2 derived polypeptides. The positions of molecular mass markers (kDa) are also shown in (a).
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examine this possibility for the C-terminus of PB2, we
tested the ability of sepharose-bead immobilized GST–NP
to bind radiolabeled PB1 in the presence and absence of
soluble MBP-PB2-C. As we have previously shown (Med-
calf et al., 1999), radiolabeled PB1 from Xenopus oocytes
bound to GST–NP but not to GST alone (Fig. 5a, lanes 2
and 3). Binding was not reduced by the addition of a
fivefold molar excess (with respect to GST–NP) of MBP
(Fig. 5a, lane 1). However, the addition of equimolar and
higher ratios of MBP-PB2-C reduced the amount of PB1
precipitated (lanes 5–7), suggesting that PB1 was preferen-
tially binding to the fragment of PB2 and was no longeravailable to interact with NP. Similar results were obtained
when PB1 expressed in E. coli or BHK cells was used as the
target (data not shown), and when the amount of bound PB1
was quantified, it was found that on average, a twofold
molar excess of the PB2 fragment inhibited the NP–PB1
interaction by around 50%, and that a sixfold excess was
sufficient to almost abolish binding (Fig. 5b). Next, we
carried out the analogous experiment with the N-terminus of
PB2. Because the N-terminal region of PB2 was available as
a GST fusion, we tested its ability to interfere with the
interaction between immobilized MBP–NP and PB1. PB1
bound efficiently to MBP–NP in the absence of GST-PB2-
N (Fig. 5a, lane 8) but not to MBP alone (lane 13). The
Fig. 5. Competitive protein–protein interactions among PB2, NP, and PB1. (a) The ability of immobilized GST [()], GST–NP, MBP–NP, or GST-PB2-N
(150 nM) to bind radiolabeled PB1 synthesized in Xenopus oocytes in the presence and absence of the indicated amounts of competitor polypeptides was
tested. Bound PB1 (arrow) was detected by SDS-PAGE and autoradiography. (b, c, d). Bound PB1 was quantified by densitometry and plotted as a percentage
of the amount bound in the absence of competitor. Values plotted are (b) the mean F SE from five independent experiments utilizing PB1 synthesized in
oocytes, BHK cells, or E. coli as a target, (c, d) the mean F SE from three independent experiments utilizing PB1 synthesized in oocytes.
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on the NP–PB1 interaction (lane 14). However, the addition
of increasing amounts of GST-PB2-N to the reactions
caused a titratable decrease in PB1 binding (lanes 9–12)
indicating that it too was able to interfere with the NP–PB1
interaction. In replicate experiments, a twofold molar excess
of the N-terminus of PB2 inhibited the NP–PB1 interaction
by around 50% and a fivefold excess by 80% (Fig. 5c).
Thus, we conclude that both N- and C-terminal sequences of
PB2 can bind either NP or PB1, but not both simultaneous-
ly. Next, we carried out the reciprocal experiment of testing
the ability of purified soluble NP to interfere with the
interaction between PB1 and immobilized PB2. As before,
radiolabeled PB1 bound to GST-PB2-N but not to GST (Fig.
5a, lanes 20 and 27, respectively). Addition of up to a 100-
fold molar excess of MBP to the reaction had little effect on
the PB2–PB1 interaction (Fig. 5a, lanes 15–19). In con-
trast, binding decreased as MBP–NP was titrated into the
reactions (lanes 21–26), with a 40-fold molar excess (with
respect to GST-PB2-N) causing a decrease in binding of
around 50% (Fig. 5d). This further confirms the competitive
nature of the interactions among NP, PB2, and PB1. Inaddition, the finding that NP is a much less effective
competitor of the PB1–PB2 interaction than PB2 is of
NP–PB1 binding suggests that PB1 binds to PB2 with
higher affinity than it does NP.
Effect of the PB2 protein-binding regions on virus
transcription
To further examine the functional role of the PB2 protein-
binding regions, we tested their ability to act as trans-
dominant inhibitors of virus gene expression, reasoning that
they might compete with WT PB2 for NP and PB1 binding.
To permit expression of the desired PB2 fragments in
mammalian cells, the GST, GST-PB2-N, and GST-PB2-C
coding regions were subcloned into plasmid pKT-0 (Tibbles
et al., 1995) under the control of a bacteriophage T7 RNA
polymerase promoter (see Materials and methods). CV-1
cells were multiply infected with recombinant vaccinia
viruses expressing the three influenza virus P proteins (Smith
et al., 1987) and the bacteriophage T7 RNA polymerase
(vTF-7; Fuerst et al., 1987), and transfected with a synthetic
RNA containing a negative sense CAT gene flanked by
Fig. 6. Ability of GST, GST-PB2-C, and GST-PB2-N to act as trans-
dominant inhibitors of virus gene expression. CV-1 cells were infected with
recombinant vaccinia viruses expressing the three subunits of the influenza
virus RNA polymerase and transfected with 1 Ag each of a synthetic
influenza virus RNA segment containing an antisense CAT gene and the
indicated pKT plasmid. In some cases, NP expression was obtained from
transfection of plasmid pKT5 (1 Ag) and superinfection with a recombinant
vaccinia virus expressing T7 RNA polymerase (+T7). Alternatively, T7
RNA polymerase was omitted and NP expression was obtained from a
recombinant vaccinia virus (T7). The resulting accumulation of CAT
polypeptide was quantified and plotted as a percentage of the value
obtained in the absence of a competitor plasmid. (+T7) Values are the
averageF SE from three independent experiments, (T7) values are from a
single experiment.
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CAT; generous gift of Dr. Mark Krystal) as well as with
plasmid pKT5, encoding influenza virus NP (Digard et al.,
1999) and the pKT GST plasmids. In certain reactions,
plasmid pKT 5 and vaccinia virus vTF-7 were omitted and
replaced with NP-VAC (Smith et al., 1987) to obtain expres-
sion of the influenza virus RNP polypeptides in the absence
of T7 RNA polymerase. In the absence of competitor plas-
mids, the WT influenza RNP polypeptides transcribed the
PB2-CAT RNA to give rise to CAT polypeptide expression,
which was then quantified by ELISA. After subtraction of the
background expression obtained in the absence of an NPFig. 7. Effect of varying PB2, NP, or PB1 concentration on the inhibitory activities
T7 and vac-PA, transfected with pKT5 and the synthetic influenza CAT segment, in
PB2-N (300 ng) as labeled. PB1 and PB2 were supplied by infection with vac-PB1
replaced with plasmids pKT1 or pKT2 as indicated. NP was supplied by transfe
harvested after 24–36 h and CAT accumulation measured by ELISA. Results
transfected pKTGST-family plasmid. (a) Effect of varying PB2 levels by transfec
transfecting the indicated amounts of pKT5. The mean and SE from three indep
while the result from a single experiment is shown for pKT-GST. (c) Effect of va
inhibition by GST-PB2-N. The average and range of two experiments are shown. (
supplied either by transfection of pKT1 or by infection with vac-PB1 (as labeled). T
PB1 MOIs of 3 and 10 are shown. (e) PB1 expression levels. Lysates from equal n
infected (V) with vac-PB1 (MOI 3) were analyzed by SDS-PAGE and Western bgene, this value was used as a baseline with which to compare
virus gene expression in the presence of the competitor
plasmids. Co-transfection of plasmids pKT-0 or pKT-GST
had relatively little effect on CATsynthesis (Fig. 6), reducing
expression less than twofold. However, co-transfection of
plasmids expressing the N- or C-termini of PB2 fused to GST
reduced expression dramatically: to around 15% of normal
levels in GST-PB2-C and 2% with GST-PB2-N (Fig. 6). This
inhibition depended on expression of the PB2 fragments and
could not be ascribed to trivial interference with the trans-
fection procedure, as no substantial inhibition was observed
from co-transfection of any of the plasmids in the absence of
T7 RNA polymerase (Fig. 6). Thus, both the N- and C-
terminal protein binding domains of PB2 act as trans-dom-
inant inhibitors of viral gene expression.
Dominant-negative inhibition by the PB2 fragments is
most readily explained by the interaction of the defective
mutants with other essential components of the transcrip-
tase, either by binding to and inactivating RNPs or by
sequestration of limiting factors and preventing the assem-
bly of active RNPs. Indeed, the N-terminal 124 amino acids
of PB2 have previously been shown to act as a dominant
negative inhibitor of virus transcription and the interference
plausibly ascribed to competition for PB1 (Perales et al.,
1996). To further examine this issue, we examined the effect
of varying the levels of WT PB2, NP, and PB1 on trans-
dominant inhibition by the PB2 fragments. First, we tested
the effects of varying the concentration of WT PB2. Cells
were infected with the recombinant vaccinia viruses, trans-
fected with the negative sense CAT RNA and plasmid pKT5
in the presence or absence of the pKT-GST-PB2 plasmids as
before, except that WT PB2 was supplied by the transfec-
tion of varying amounts of plasmid pKT2. The cells were
subsequently lysed and CAT accumulation measured as a
percentage of that observed in the absence of any competitor
plasmid. Parallel Western blot analysis of PB2 levels con-
firmed that increasing the dose of plasmid pKT2 did lead to
the synthesis of greater amounts of PB2 (data not shown).
At low doses of WT PB2, both GST-PB2 fusions caused a
greater than 90% reduction in CAT accumulation (Fig. 7a).
However, this inhibition was markedly decreased by the co-
transfection of larger amounts of plasmid pKT2, in the N-
terminal fragment of PB2, to levels similar to that observedof GST, GST-PB2-C, and GST-PB2-N. CV-1 cells were infected with vac-
the absence or presence of pKTGST, pKTGST-PB2-C (1 Ag), or pKTGST-
and vac-PB2, respectively, except in specific experiments where they were
ction of plasmid pKT5 (1 Ag except where labeled otherwise). Cells were
are expressed as the % CAT accumulation observed in the absence of a
tion of the indicated amounts of pKT2. (b) Effect of varying NP levels by
endent experiments are plotted for pKT GST-PB2-C and pKTGST-PB2-N,
rying PB1 concentration by transfecting the indicated amounts of pKT1 on
d) Effect of PB1 expression method on inhibition by GST-PB2-C. PB1 was
he average and range of two experiments using 50 and 170 ng pKT1 or vac-
umbers of cells transfected with the indicated amounts of plasmid pKT1 or
lotting with anti-PB1 serum.
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domains of PB2 competing with WT PB2 for other tran-
scription factors.
Next, we carried out a similar experiment where the
amount of NP was varied by transfecting varying amountsof plasmid pKT5. Expression of GST alone resulted in
only minimal decreases in CAT accumulation, regardless of
the NP dose (Fig. 7b). In contrast, co-expression of GST-
PB2-C caused inhibition of CAT accumulation by around
70%, although this was similarly independent of NP
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likewise caused inhibition of CAT accumulation, by up
to 95%. Unexpectedly however, trans-dominant inhibition
by GST-PB2-N was partially relieved by decreasing the
amount of NP and was exacerbated by increasing the
amount (Fig. 7b). In replicate experiments, a tenfold
increase in the amount of NP plasmid transfected caused
on average a sixfold increase in the level of inhibition
caused by a constant amount of pKTGST-PB2-N. This NP-
dependent variation is consistent with the in vitro data
indicating a protein–protein interaction between the N-
terminus of PB2 and NP (Figs. 1, 4, and 5).
When the matching experiment was carried out for
PB1, increasing the dose of plasmid pKT1 from 50 to
500 ng/transfection resulted in a decrease in inhibition by
pKTGST-PB2-N (Fig. 7c). The decrease was relatively
small, but reproducible as in three independent experi-
ments a tenfold increase in transfected PB1 plasmid
increased CAT expression by 2.0 F 0.1-fold. In addition,
a similar magnitude decrease in inhibition was obtained by
increasing the MOI of PB1-VAC tenfold (data not shown).
When the same methodology was applied to the C-termi-
nal fragment of PB2, an unexpected but clear qualitative
difference in the effect of GST-PB2-C on influenza virus
gene expression that depended on the source of PB1
became apparent. While co-transfection of pKTGST-PB2-
C reproducibly inhibited CAT expression when PB1 was
expressed from PB1-VAC (Figs. 6 and 7a, b, d), it
stimulated it when PB1 was supplied by transfection of
plasmid pKT1 (Fig. 7d). In four replicate experiments,
pKTGST-PB2-C stimulated transcription driven by the
optimal amount of pKT1 (50 ng) to an average of 200%
of the baseline value. Western blot analysis of the PB1
content of cells indicated that T7 RNA polymerase-driven
expression from even moderate amounts of plasmid pKT1
produced higher quantities of PB1 than infection with the
recombinant vaccinia virus PB1-VAC (Fig. 7e, compare
lanes 1 and 4). However, immunofluorescence analysis
showed that although infection with vac-PB1 resulted in
PB1 expression in almost every cell, transfection with
plasmid pKT1 was less than 10% efficient (data not
shown). Thus, plasmid-driven expression of PB1 results
in substantially higher levels of PB1 per cell. This there-
fore suggests that the modulatory effect of the C-terminal
domain of PB2 on virus transcription is dependent upon
PB1 levels, again, consistent with the in vitro protein–
protein interactions.Discussion
Assembly and transcriptional activity of influenza virus
RNPs depend on a complex network of protein–protein
and protein–RNA interactions among the three subunits of
the polymerase, NP, and both viral and cellular RNAs. In
the absence of any high-resolution structural informationfor the RNPs, many molecular–genetic studies have been
directed at mapping the functional regions of the protein
components. In addition to biochemical and mutational
analysis of catalytic centers (Asano and Ishihama, 1997;
Biswas and Nayak, 1994; Li et al., 2001), several studies
have examined sequences involved in protein–RNA con-
tacts (Albo et al., 1995; Elton et al., 1999b; Fechter et al.,
2003; Gonzalez and Ortin, 1999a, 1999b; Honda et al.,
1999; Kobayashi et al., 1994; Li et al., 1998, 2001) and
protein–protein contacts in the RNP. These latter analyses
have identified regions of the P proteins involved in
forming the polymerase heterotrimer (Biswas and Nayak,
1996; Gonzalez et al., 1996; Ohtsu et al., 2002; Perez and
Donis, 1995; Toyoda et al., 1996; Zurcher et al., 1996),
and NP sequences involved in forming homo-oligomers
and contacting PB2 (Biswas et al., 1998; Elton et al.,
1999a). In this study, we extend knowledge of RNP
protein–protein contacts by identifying for the first time
regions of the polymerase that bind NP. These data permit
the drawing of a more detailed functional map of the PB2
protein, containing information on NP-interacting sequen-
ces and a hitherto unidentified PB1-binding domain (Fig.
8). Our finding that two separate regions of PB2 are
capable of binding NP is consistent with that of Biswas
et al. (1998) that conversely, multiple regions of NP
interact with PB2. The identification of a novel C-terminal
PB1-binding domain in PB2 contradicts an earlier study
that found no evidence for PB1-binding activity in N-
terminally deleted PB2 fragments (Toyoda et al., 1996).
However, we note that a subsequent study from the same
laboratory using identical expression and immunoprecipi-
tation conditions and some of the original plasmid con-
structs did detect coprecipitation of PB1 and mutant PB2
molecules lacking up to the first 205 amino acids (Ohtsu et
al., 2002). Further N-terminal truncations were not ana-
lyzed in the second study and the data were interpreted in
light of the known N-terminal PB1-binding sequence.
However, the data are equally consistent with the results
presented here indicating the presence of a second PB1-
binding site in PB2. The definition of a second PB1-
binding site in PB2 may well provide an explanation for
why the study of Biswas and Nayak (1996) identified a
different region of PB1 as important for binding PB2
compared to the studies of Toyoda et al. (1996) and
Gonzalez et al. (1996). Our results confirm that the C-
terminus of PB1 does bind the N-terminus of PB2 (Fig. 1a,
lanes 7–12), suggesting that conversely, the C-terminal
binding domain of PB2 might interact with the more N-
terminal region of PB1 identified by Biswas and Nayak
(1996).
The NP- and PB1-binding sites identified here show
considerable overlap with each other at the sequence level,
which a series of competitive binding experiments showed
to also operate at the functional level (Fig. 5). The binding
sites also show a degree of overlap with sequences proposed
by others as being involved in mRNA cap binding (Fig. 8;
Fig. 8. Functional domains of PB2. The minimal identified sequences capable of binding PB1 (green boxes) and NP (blue boxes) are depicted relative to a
linear representation (scale bar calibrated in amino acids) of the PB2 molecule, while sequences implicated in cap binding are shown in red. Black bars indicate
sequences implicated in the nuclear localization of PB2. NP- and PB1-binding domains: this study. N-terminal (N), middle (M), and C-terminal (C) cap-binding
sequences: de la Luna et al. (1989), Fechter et al. (2003), Honda et al. (1999), Li et al. (2001). NLS sequences: Mukaigawa and Nayak (1991).
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However, we found no evidence for cap- or RNA-binding
activity in the purified PB2 fusion proteins employed in this
study (data not shown).
Both NP/PB1-binding domains of PB2 acted as trans-
dominant inhibitors of the viral RNA polymerase in a
recombinant virus gene expression assay, further confirming
their functional importance (Fig. 6). A previous study noted
the inhibitory effect of co-expressing an N-terminal frag-
ment of PB2 on RNP function and proposed that the
inhibition resulted from competition with the WT protein
for PB1 (Perales et al., 1996). Supporting this hypothesis,
we found that the inhibitory potential of the N- and C-
terminal fragments of PB2 depended on the amount of WT
PB2 and PB1 (Fig. 7). However, the inhibitory activity of
the N-terminal PB2 fragment also depended upon the
expression levels of NP, consistent with its identification
as an NP-binding domain. The somewhat surprising finding
that increased expression levels of NP potentiated its inhib-
itory activity might reflect the mutually incompatible trian-
gle of protein–protein interactions among the PB1, PB2,
and NP polypeptides, or that the N-terminal fragment of
PB2 only inhibits virus transcription when complexed with
NP. It may also result from suboptimal or unbalanced
expression levels of the individual RNP components in
the recombinant systems employed here. This could also
explain the finding that the C-terminal domain of PB2 is
inhibitory in the presence of (relatively) low levels of PB1
but stimulatory in the presence of high amounts of the
protein (Fig. 7d). Overall however, the abilities of the N-
and C-terminal PB2 domains to modulate RNP transcrip-
tional activity in a manner dependent on the concentration
of NP and PB1 suggest that the protein–protein interactions
identified here are functionally important.
What functions might the PB1–PB2–NP interactions
play? The finding that each PB2 domain can bind either
NP or PB1 but not both simultaneously is suggestive of a
regulatory role. We have previously suggested that one
function of a P protein–NP interaction might be to ensure
processive RNA synthesis (Medcalf et al., 1999). This
hypothesis is supported by the finding that NP is necessary
for the transcription of full-length genome segments (Honda
et al., 1988) and is consistent with an electron microscopic
reconstruction of a recombinant RNP, which suggests thatthe polymerase complex interacts with two NP molecules
simultaneously (Martin-Benito et al., 2001). However, we
found no evidence that the N- and C-terminal PB2 frag-
ments could interfere with NP–NP or NP–RNA interac-
tions in vitro (data not shown), which might be predicted for
such a processivity function. Alternatively, it has been
hypothesized that the protein–protein interaction of NP
with the P proteins might function to alter the activity of
the polymerase complex to bias it from mRNA transcription
toward genome replication (Biswas et al., 1998; Mena et al.,
1999). Some studies (but not all; Brownlee and Sharps,
2002; Lee et al., 2002; Perales and Ortin, 1997) have found
evidence that complexes of PB1 and PA might be able to
synthesize cRNA in the absence of PB2 (Honda et al., 2002;
Nakagawa et al., 1995, 1996). In the absence of any
evidence for subcomplexes of the P proteins in vivo, it
has been suggested that the viral replicase might consist of a
trimeric complex in which PB2 has been functionally
disabled (Honda et al., 2002). The demonstration here that
PB2 contains two separate regions that can bind either PB1
or NP but not both suggests the possibility that a polymerase
complex containing one molecule of each P protein and NP
could form in which a PB2–PB1 contact was replaced by a
PB2–NP interaction. If the absent PB1–PB2 interaction
was functionally important for mRNA synthesis, such a
tetrameric complex might form a replicase. This hypothesis
is consistent with our finding that the co-expression of the
individual PB2 fragments inhibited viral gene expression, if
one postulates that the PB2 domains functioned as NP
analogues. We have been unable to determine whether the
PB2 fragments inhibit all forms of viral RNA synthesis or
only mRNA transcription because the low efficiency of the
transfection system renders unambiguous detection of
cRNA difficult. However, the identification of single amino
acid substitutions in NP and PB2 that inhibit NP–PB2
binding without affecting other functions of the polypep-
tides would provide an alternative way of testing the
hypothesis that an NP–PB2 interaction promotes genome
replication. We note that a recent study identified a series of
point mutations in the N-terminal region of PB2 that inhibit
genome replication without apparent effects on PB1-binding
or mRNA transcription (Gastaminza et al., 2003). In light of
the results presented here, it would be interesting to test the
effects of these mutations on NP binding.
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Antisera and plasmids
A set of rabbit sera raised against defined regions of PB2
(expressed in E. coli as fusion proteins with h-galactosi-
dase) has already been described (Blok et al., 1996). In
some cases, a GST–PB1 fusion protein containing the C-
terminal 75 amino acids of PB1 (GST-1N683: see later for
construction) was used to precipitate N-terminal fragments
of PB2, to avoid use of the low titer PB2 F1 serum. The
design of this fusion protein is based on the results of our
own unpublished experiments mapping the PB1 sequences
important for binding PB2, which are in broad agreement
with the results of others (Gonzalez et al., 1996; Toyoda et
al., 1996). The anti-PB1 sera used were generated by
immunizing rabbits with h-galactosidase fusion proteins
containing aa 50–370 (F1; Digard et al., 1989) or aa
421–665 (F3). Plasmids containing cDNA copies of the
wild-type P protein genes flanked by 5V- and 3V-nontrans-
lated regions of the Xenopus h-globin gene, under the
control of either bacteriophage SP6 or T7 RNA polymerase
promoters (pKT series), have previously been described
(Blok et al., 1996; Digard et al., 1989). Deletion mutations
were created using convenient restriction enzyme sites in the
wild-type P genes, or in some cases, a unique SnaBI site
introduced by ligating the oligonucleotide TGGTACG-
TACCA into a desired restriction enzyme site, and standard
recombinant DNA methodology to generate plasmids lack-
ing specified portions of the P genes. In the interest of
brevity, details of the cloning steps are not reported here, but
are available on request. N-terminally deleted (N) mutants
are named according to the first codon of the WT sequence
present, C-terminally truncated (C) mutants according to the
last. All C-terminal deletion constructs encode between 1
and 6 additional non-influenza-derived residues at the 3V-end
of the ORF as a results of the DNA cloning procedures. A
plasmid directing the synthesis of a GST–NP fusion protein
has been described previously (Digard et al., 1999). GST–
PB1 gene fusions were constructed by excising fragments
from PB1 cDNA cloned into pKT1 by digestion with either
ScaI (at nucleotide coordinate 2067) and SmaI (3V to PB1
gene), or EcoRV (2154 and 3V to PB1 gene), and ligating
them into pGEX-4T-1 digested with SmaI (Smith and
Johnson, 1988; Pharmacia). The resulting plasmids pGEX-
1N683 and pGEX-1N712 contained amino acid codons 683
or 712–757, respectively, fused in frame to the 3V-end of the
GST open reading frame, separated by a short linker
sequence containing a thrombin protease recognition se-
quence. GST-PB2 gene fusions were constructed similarly
using segment 1 cDNA from plasmid pKT2 or pVB2 (Blok
et al., 1996). Plasmid pGEX2 N489 utilized ScaI (nucleo-
tide 1489) and XbaI (3V to PB2 gene and end filled) and
pGEX 4T-3 digested with SmaI. Plasmid pGEX 2N580
utilized Asp 700 (nucleotide 1763) and XbaI (end filled)
and pGEX 4T-1 digested with SmaI. Plasmid pMAL-2N580was created by a similar strategy except that a 3V-PB2 gene
fragment obtained by digestion with Asp 700 and SalI was
first subcloned into plasmid pGAD424 (Clontech), removed
by digestion with EcoRI, and then inserted into plasmid
pMAL-c2 digested with EcoRI. As with the GST PB1
constructs, the GST and PB2 coding regions were separated
by a short linker sequence containing a thrombin protease
recognition sequence. To express N-terminal sequences of
PB2, plasmid pGEX-2C402 was created by digestion of
pVB2 with BamHI (5V to PB2 coding region) and NcoI
(nucleotide 1230, end filled) and ligation of the resulting
DNA fragment into pGEX-3X digested with BamHI and
SmaI. An in frame stop-codon was then introduced after
codon 258 by ligation of the commercial oligonucleotide
5V-CTAGTCTAGACTAG-3V (New England Biolabs; XbaI
linker) into the HindIII site (after end-repair) at nucleotide
798 of the PB2 gene. To permit T7 RNA polymerase-driven
expression of GST and GST-PB2 fusions, the oligonucleo-
tide primers 5V-CAGGAAACAGTATTCATGTC-3V and 5V-
CGCGAGGCAGATCGTCAGTC-3Vwere used to PCR am-
plify the appropriate sequences from plasmids pGEX-2C258
and pGEX-2N580 that were then cloned into plasmid pKT-0
(Tibbles et al., 1995) to create plasmids pKTGST-2C258 and
pKTGST-2N580, respectively. To create a plasmid that
expressed nonfused GST under the control of a T7 RNA
polymerase promoter, pKTGST-2C258 was digested with
BamHI to excise the PB2 coding region and religated with
the addition of the XbaI oligonucleotide linker to create
plasmid pKT-GST.
Expression and purification of fusion proteins
NP fused to either MBP or GSTwas purified from E. coli
containing the appropriate plasmids as described previously
(Digard et al., 1999; Frangioni and Neel, 1993). Purified
proteins were dialysed against 10 mM HEPES, pH 7.6, 50
mM NaCl, 0.1 mM EDTA, 1 mM DTT, and 10% glycerol,
and stored at 70 jC. Where required, fusion proteins were
also left bound to sepharose beads, resuspended in an equal
volume of 100% glycerol, and stored at 20 jC.
RNA transcription, in vitro translation, microinjection, and
immunoprecipitations
Capped RNAs were generated by in vitro transcription of
the appropriate linearized plasmids as previously described
(Digard et al., 1989). In the case of plasmid constructs that
lacked the Xenopus h-globin 3V non-coding sequence, poly-
adenylated RNA was generated by the inclusion of 32 U/
Al of poly(A) polymerase (GIBCO-BRL) in the transcription
reaction. Radiolabeled NP polypeptides were synthesized
using a coupled in vitro transcription–translation system as
previously described (Elton et al., 1999a). Oocytes were
taken from frogs, maintained, and microinjected as previ-
ously described (Blok et al., 1996; Digard et al., 1989).
Oocytes were injected with around 25 ng of each mRNA in
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transferred to Modified Barth’s Saline containing [35S]-
methionine at 1.0 mCi/ml (10 Al/oocyte) and incubated for
5 h. Subsequently, the oocytes were harvested by mechan-
ical disruption into 50 mM Tris–Cl, pH 7.6, 100 mM KCl, 5
mM MgCl2, 10% glycerol, 1 mM DTT, and the extracts
clarified by centrifugation. In some experiments, radiola-
beled PB1 was prepared from BHK cells transfected with
plasmid pKT1, infected with vaccinia virus vTF-7, and
incubated overnight in the presence of [35S]-methionine.
For immunoprecipitation, aliquots (5–10 Al, containing the
equivalent of half to one oocyte) were diluted into 100 Al of
high detergent immunoprecipitation (IP) buffer (50 mM
Tris–Cl, pH 7.6, 100 mM KCl, 5 mM MgCl2, 1 mM
DTT, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS), and left on ice for 30 min before the addition of up to
4 Al antiserum. After a further 1 h on ice, 50 Al of a 50% (v/
v) suspension of protein-A sepharose (Sigma) in high
detergent IP buffer was added and the samples incubated
with gentle mixing for 30 min at room temperature. Sephar-
ose-bound material was collected by centrifugation, washed
twice with 750 Al of high detergent IP buffer, once with a
similar volume of low detergent IP buffer (containing 0.1%
Nonidet P-40 as the only detergent) before elution by
boiling in SDS-PAGE sample buffer. Radiolabeled proteins
were then separated by polyacrylamide gel electrophoresis
and detected by autoradiography.
Binding studies with GST fusion proteins
GST fusion proteins (typically 0.3 Ag) were diluted in
100 Al of low detergent IP buffer containing 1 mM DTT,
mixed with 1–2 Al of [35S]-methionine labeled oocyte
lysate, and incubated at room temperature for 1 h before
the addition of 40 Al of a 50% (v/v) suspension of
glutathione sepharose in PBS. After 30 min incubation
with gentle mixing at room temperature, the solid phase
was collected by centrifugation, washed three times with
750 Al of low detergent IP buffer, and bound material
eluted by boiling in SDS-PAGE sample buffer. Precipitated
polypeptides were separated by SDS-PAGE, nonradioac-
tive proteins detected by staining with Coomassie brilliant
blue dye (to confirm precipitation of the GST fusion
proteins), and radiolabeled polypeptides detected by auto-
radiography. Binding was quantified by densitometry of
the exposed X-ray films as previously described (Digard et
al., 1999).
Influenza virus gene expression assay
For in vivo transcription assays, a synthetic influenza
genome segment containing an antisense chloramphenicol
acetyl transferase (CAT) gene was produced by in vitro
transcription of plasmid pPB2CAT9 (generous gift of Dr.
Mark Krystal). The three polymerase proteins and NP were
supplied by either infection with recombinant vacciniaviruses (PB1-, PB2-, PA-, and NP-VAC; Smith et al.,
1987) or by infection with a vaccinia virus that expresses
the bacteriophage T7 RNA polymerase (VTF-7; Fuerst et
al., 1987) and transfection with a plasmid containing a
cDNA copy of the appropriate influenza virus gene (pKT1,
2, 3, 5 for PB1, PB2, PA, and NP, respectively) under the
control of a T7 RNA polymerase promoter. BHK or CV-1
cells (in 6-well plates) were infected with recombinant
vaccinia viruses at a multiplicity of infection of 5 of each
virus per cell for 2 h at 37 jC. The cells were washed 3
times with serum-free medium before transfection with up
to 1 Ag of each individual plasmid and 0.5 Ag of
pPB2CAT9 in vitro transcribed RNA and 10 Ag of a
cationic liposome mixture (Escort; Sigma-Aldrich), accord-
ing to the manufacturers’ instructions. The cells were
incubated at 37 jC for 20 h, washed 3 times with ice-
cold PBS, and solubilized in 1 ml of CAT ELISA lysis
buffer (Boehringer Mannheim). The lysate was clarified by
centrifugation at 14000  g for 10 min at 4 jC and CAT
expression quantified relative to known standards by a
commercial enzyme-linked immunosorbent assay (Boeh-
ringer Mannheim). Initial titration experiments established
that the optimal amounts of each plasmid required were 50
ng for the polymerase subunits and 1 Ag for NP (data not
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